JP6942726B2 - クロメン化合物および第２活性薬剤の併用薬 - Google Patents

クロメン化合物および第２活性薬剤の併用薬 Download PDF

Info

Publication number
JP6942726B2
JP6942726B2 JP2018554651A JP2018554651A JP6942726B2 JP 6942726 B2 JP6942726 B2 JP 6942726B2 JP 2018554651 A JP2018554651 A JP 2018554651A JP 2018554651 A JP2018554651 A JP 2018554651A JP 6942726 B2 JP6942726 B2 JP 6942726B2
Authority
JP
Japan
Prior art keywords
compound
combination
formula
cancer
another embodiment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018554651A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019501224A (ja
JP2019501224A5 (enExample
Inventor
ジェイ． タリー，ジョン
ジェイ． タリー，ジョン
ダブリュ． サンデージ，ボビー
ダブリュ． サンデージ，ボビー
ジェイ． マルティネス，エドゥアルド
ジェイ． マルティネス，エドゥアルド
Original Assignee
ユークリセス ファーマシューティカルズ，インコーポレイテッド
ユークリセス ファーマシューティカルズ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユークリセス ファーマシューティカルズ，インコーポレイテッド, ユークリセス ファーマシューティカルズ，インコーポレイテッド filed Critical ユークリセス ファーマシューティカルズ，インコーポレイテッド
Publication of JP2019501224A publication Critical patent/JP2019501224A/ja
Publication of JP2019501224A5 publication Critical patent/JP2019501224A5/ja
Application granted granted Critical
Publication of JP6942726B2 publication Critical patent/JP6942726B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrane Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
JP2018554651A 2016-01-08 2017-01-09 クロメン化合物および第２活性薬剤の併用薬 Active JP6942726B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662276713P 2016-01-08 2016-01-08
US62/276,713 2016-01-08
US201662277225P 2016-01-11 2016-01-11
US62/277,225 2016-01-11
PCT/US2017/012737 WO2017120591A1 (en) 2016-01-08 2017-01-09 Combination of a chromene compound and a second active agent

Publications (3)

Publication Number Publication Date
JP2019501224A JP2019501224A (ja) 2019-01-17
JP2019501224A5 JP2019501224A5 (enExample) 2020-02-13
JP6942726B2 true JP6942726B2 (ja) 2021-09-29

Family

ID=59274050

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018554651A Active JP6942726B2 (ja) 2016-01-08 2017-01-09 クロメン化合物および第２活性薬剤の併用薬

Country Status (8)

Country Link
US (2) US20170196835A1 (enExample)
EP (1) EP3400218A4 (enExample)
JP (1) JP6942726B2 (enExample)
KR (1) KR20180100652A (enExample)
CN (1) CN108779091B (enExample)
AU (1) AU2017206108B2 (enExample)
MX (1) MX388579B (enExample)
WO (1) WO2017120591A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109311858B (zh) 2016-05-26 2021-12-03 里科瑞尔姆Ip控股有限责任公司 Egfr抑制剂化合物
US20200131270A1 (en) * 2017-07-20 2020-04-30 National University Corporation Hokkaido University Combination use of inhibitor targeting pd-1/pd-l1 and cox-2 inhibitor
TR201900059A2 (tr) 2018-01-05 2019-07-22 Gnt Biotech & Medicals Corp Bi̇r farmasöti̇k kombi̇nasyon ve tümör mi̇kroortaminin ve i̇mmünoterapi̇ni̇n regülasyonu i̇çi̇n yöntem
TWI869398B (zh) * 2019-05-10 2025-01-11 英商拜西克爾德有限公司 治療癌症之方法
EP4051260A4 (en) * 2019-10-28 2023-12-06 Enzychem Lifesciences Corporation METHODS AND COMPOSITIONS FOR TREATING CANCER
CN118286450A (zh) 2019-11-12 2024-07-05 纳米医疗有限公司 用于治疗癌症的含有ido拮抗剂前药的调配的和/或共同调配的脂质体组合物及其方法
AU2021263914B2 (en) 2020-04-29 2026-07-23 D.E. Shaw Research, Llc PI3K-α inhibitors and methods of use thereof
CN118541368A (zh) * 2021-09-03 2024-08-23 比西恩生物科学有限责任公司 使用bcn057、bcn077及类似物的治疗方法
EP4412606A4 (en) * 2021-10-07 2025-09-24 Relay Therapeutics Inc PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF
KR102889598B1 (ko) * 2023-02-16 2025-11-21 주식회사 재인알앤피 신규한 데커신 유도체, 및 이의 비소세포폐암 예방 또는 치료 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US20020103141A1 (en) 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
US20040127470A1 (en) 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
EP2175722A4 (en) 2007-07-12 2010-08-25 Tragara Pharmaceuticals Inc PATIENT SELECTION AND THERAPEUTIC PROCEDURES WITH PROSTAGLAND INMETABOLISM MARKERS
CN102757417B (zh) 2012-06-18 2014-09-24 中国科学院广州生物医药与健康研究院 氘代苯并吡喃类化合物及其应用
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
CN103044477B (zh) 2012-12-07 2015-08-05 中国科学院广州生物医药与健康研究院 三甲基硅取代苯并吡喃类化合物及其应用
CN103012350B (zh) * 2012-12-07 2015-02-04 中国科学院广州生物医药与健康研究院 苯并吡喃类手性化合物的合成方法
US9452228B2 (en) 2013-04-01 2016-09-27 Immunomedics, Inc. Antibodies reactive with an epitope located in the N-terminal region of MUC5AC comprising cysteine-rich subdomain 2 (Cys2)
CN105073128A (zh) * 2013-04-03 2015-11-18 Ibc药品公司 用于诱导对疾病的免疫应答的组合疗法
WO2015094996A2 (en) 2013-12-17 2015-06-25 Merck Sharp & Dohme Corp. Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
WO2015191568A2 (en) 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature

Also Published As

Publication number Publication date
KR20180100652A (ko) 2018-09-11
US20170196835A1 (en) 2017-07-13
MX388579B (es) 2025-03-20
EP3400218A1 (en) 2018-11-14
WO2017120591A1 (en) 2017-07-13
CN108779091B (zh) 2022-12-27
MX2018008433A (es) 2019-03-28
AU2017206108A1 (en) 2018-08-02
US20220265602A1 (en) 2022-08-25
CA3010848A1 (en) 2017-07-13
AU2017206108B2 (en) 2021-10-28
JP2019501224A (ja) 2019-01-17
EP3400218A4 (en) 2019-09-18
CN108779091A (zh) 2018-11-09
US12544356B2 (en) 2026-02-10

Similar Documents

Publication Publication Date Title
US12544356B2 (en) Combination of a chromene compound and a second active agent
EP4323066A1 (en) Mek inhibitors and uses thereof
KR102705821B1 (ko) 항암제
JP2023553866A (ja) Ｔｅａｄ阻害剤、及びその使用
JP2020169223A (ja) 癌の治療に使用するための癌幹細胞性阻害剤および免疫療法剤を含む組成物
KR20190067235A (ko) Vista 및 pd-1 경로의 이중 억제제
JP2024514836A (ja) Ｃｂｌ－ｂ阻害化合物との組み合わせ療法
JP7246309B2 (ja) 免疫応答を調節するためのオキサビシクロヘプタン
JP2016539156A (ja) オーロラキナーゼ阻害剤と抗ｃｄ３０抗体の併用
JP7028765B2 (ja) ベンズアミドおよび活性化合物組成物および使用方法
AU2019210332A1 (en) Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
CA3107023A1 (en) Ep4 inhibitors and synthesis thereof
JP2023509359A (ja) 鉄依存性細胞分解の誘導物質との併用抗癌療法
WO2017201043A1 (en) Combination therapy for treating cancer
TW201815417A (zh) Ｐｄ－１抗體與ｉｄｏ抑制劑聯合在製備抗腫瘤的藥物中的用途
JP7492752B2 (ja) 免疫療法のためのアジュバントとしてのグアナベンズ
JP7636322B2 (ja) 癌を処置するためのマドラシン誘導体化合物、組成物およびこれらの使用
CA3010848C (en) Combination of a chromene compound and a second active agent
HK40000167B (en) Combination of a chromene compound and a second active agent
HK40000167A (en) Combination of a chromene compound and a second active agent
WO2026097102A1 (en) Methods for the treatment of cancer using microtubule targeting agents in combination with immune checkpoint modulators
EA048934B1 (ru) Способы лечения рака
HK40061214A (en) Cinnoline compounds and for the treatment of hpk1-dependent disorders such as cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210727

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210810

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210908

R150 Certificate of patent or registration of utility model

Ref document number: 6942726

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250